Endocrine Disorders

Consistent benefits seen for White and Asian populations and consistent lack of benefits seen in Black populations.

UCMyRx exposure negatively linked to HbA1c but not to systolic BP among Hispanic patients with type 2 diabetes.

Use of analog vs human insulin in patients receiving hemodialysis is associated with a lower risk for major adverse cardiovascular events, hospitalization, and death.

Icodec with app superior to once-daily basal insulin analogues for change in glycated hemoglobin.

Significantly higher rates of hyperglycemia seen for patients treated as standard care vs those in clinical trials.

Lawsuits are meant to stop the other companies from ‘the unlawful marketing and sale of non-FDA approved compounded products.’

Safety concerns to consider for youth with diabetes who are restricting carbohydrates include growth deceleration, poor bone health.

Crinecerfort is an investigational, oral, selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist.

However, risk factors change depending on time from diagnosis and comorbidities.

Findings show low-dose aspirin also slows the increase in fasting plasma glucose over time among initially healthy older adults.

Study findings showed a marked elevation in the risks of cardiovascular outcomes in patients with deteriorating kidney function.

The benefit of aspirin in sepsis-associated AKI may relate to its anti-inflammatory and anti-platelet properties.

A PDUFA target date of December 30, 2023 has been set for this application.

Enrollees in the Medicare prescription drug program paid a total of $3.4 billion in out-of-pocket costs in 2022 for the 10 initial drugs chosen for price negotiations.

Increase in biomarkers and multimarker panel linked to increased risk for primary cardiorenal outcome.

Based on body mass index, 120 million Americans would qualify to take Wegovy.

No change in cardiometabolic risk factors or glycemic control seen over six months.

Study supports the benefit of potential new Alzheimer drug; RSV treatment approved for neonates and infants; Veklury approval expanded; a blood test used to diagnose life-threatening heart muscle injuries has been recalled; Brenzavvy available for adults.

These devices are sold in kits and manufactured by RoyalVibe Health, CellQuicken, Well-Being Reality.